Literature DB >> 30538204

Crystal structure of the human NK1 tachykinin receptor.

Jie Yin1, Karen Chapman1, Lindsay D Clark1, Zhenhua Shao1, Dominika Borek1, Qingping Xu2, Junmei Wang3, Daniel M Rosenbaum4.   

Abstract

The NK1 tachykinin G-protein-coupled receptor (GPCR) binds substance P, the first neuropeptide to be discovered in mammals. Through activation of NK1R, substance P modulates a wide variety of physiological and disease processes including nociception, inflammation, and depression. Human NK1R (hNK1R) modulators have shown promise in clinical trials for migraine, depression, and emesis. However, the only currently approved drugs targeting hNK1R are inhibitors for chemotherapy-induced nausea and vomiting (CINV). To better understand the molecular basis of ligand recognition and selectivity, we solved the crystal structure of hNK1R bound to the inhibitor L760735, a close analog of the drug aprepitant. Our crystal structure reveals the basis for antagonist interaction in the deep and narrow orthosteric pocket of the receptor. We used our structure as a template for computational docking and molecular-dynamics simulations to dissect the energetic importance of binding pocket interactions and model the binding of aprepitant. The structure of hNK1R is a valuable tool in the further development of tachykinin receptor modulators for multiple clinical applications.

Entities:  

Keywords:  GPCR; drug design; ligand recognition; substance P; tachykinin receptor

Mesh:

Substances:

Year:  2018        PMID: 30538204      PMCID: PMC6310836          DOI: 10.1073/pnas.1812717115

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   12.779


  57 in total

Review 1.  Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?

Authors:  Guy Griebel; Florian Holsboer
Journal:  Nat Rev Drug Discov       Date:  2012-05-18       Impact factor: 84.694

2.  Design and synthesis of a novel, achiral class of highly potent and selective, orally active neurokinin-1 receptor antagonists.

Authors:  Torsten Hoffmann; Michael Bös; Heinz Stadler; Patrick Schnider; Walter Hunkeler; Thierry Godel; Guido Galley; Theresa M Ballard; Guy A Higgins; Sonia M Poli; Andrew J Sleight
Journal:  Bioorg Med Chem Lett       Date:  2005-12-05       Impact factor: 2.823

Review 3.  Neurokinin-1 receptor: functional significance in the immune system in reference to selected infections and inflammation.

Authors:  Steven D Douglas; Susan E Leeman
Journal:  Ann N Y Acad Sci       Date:  2010-11-22       Impact factor: 5.691

4.  Effect of single point mutations of the human tachykinin NK1 receptor on antagonist affinity.

Authors:  K Lundstrom; A B Hawcock; A Vargas; P Ward; P Thomas; A Naylor
Journal:  Eur J Pharmacol       Date:  1997-10-15       Impact factor: 4.432

5.  Two related neurokinin-1 receptor antagonists have overlapping but different binding sites.

Authors:  S Greenfeder; B Cheewatrakoolpong; J Anthes; M Billah; R W Egan; J E Brown; N J Murgolo
Journal:  Bioorg Med Chem       Date:  1998-02       Impact factor: 3.641

6.  ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB.

Authors:  James A Maier; Carmenza Martinez; Koushik Kasavajhala; Lauren Wickstrom; Kevin E Hauser; Carlos Simmerling
Journal:  J Chem Theory Comput       Date:  2015-07-23       Impact factor: 6.006

Review 7.  Tachykinins and tachykinin receptors: structure and activity relationships.

Authors:  T A Almeida; J Rojo; P M Nieto; F M Pinto; M Hernandez; J D Martín; M L Candenas
Journal:  Curr Med Chem       Date:  2004-08       Impact factor: 4.530

8.  Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.

Authors:  J J Hale; S G Mills; M MacCoss; P E Finke; M A Cascieri; S Sadowski; E Ber; G G Chicchi; M Kurtz; J Metzger; G Eiermann; N N Tsou; F D Tattersall; N M Rupniak; A R Williams; W Rycroft; R Hargreaves; D E MacIntyre
Journal:  J Med Chem       Date:  1998-11-05       Impact factor: 7.446

9.  In vitro and in vivo characterization of the non-peptide NK3 receptor antagonist SB-223412 (talnetant): potential therapeutic utility in the treatment of schizophrenia.

Authors:  Lee A Dawson; Katherine J Cato; Claire Scott; Jeannette M Watson; Martyn D Wood; Richard Foxton; Raúl de la Flor; Gareth A Jones; James Nc Kew; Jane E Cluderay; Eric Southam; Graham S Murkitt; Jane Gartlon; Darrel J Pemberton; Declan Nc Jones; Ceri H Davies; Jim Hagan
Journal:  Neuropsychopharmacology       Date:  2007-08-29       Impact factor: 7.853

Review 10.  Tachykinin NK2 receptor antagonists for the treatment of irritable bowel syndrome.

Authors:  Alessandro Lecci; Angela Capriati; Carlo Alberto Maggi
Journal:  Br J Pharmacol       Date:  2004-03-22       Impact factor: 8.739

View more
  13 in total

Review 1.  Understanding Peptide Binding in Class A G Protein-Coupled Receptors.

Authors:  Irina G Tikhonova; Veronique Gigoux; Daniel Fourmy
Journal:  Mol Pharmacol       Date:  2019-07-10       Impact factor: 4.436

2.  Cryo-EM Structure of the Human Cannabinoid Receptor CB2-Gi Signaling Complex.

Authors:  Changrui Xing; Youwen Zhuang; Ting-Hai Xu; Zhiwei Feng; X Edward Zhou; Maozi Chen; Lei Wang; Xing Meng; Ying Xue; Junmei Wang; Heng Liu; Terence Francis McGuire; Gongpu Zhao; Karsten Melcher; Cheng Zhang; H Eric Xu; Xiang-Qun Xie
Journal:  Cell       Date:  2020-01-30       Impact factor: 41.582

3.  Human substance P receptor binding mode of the antagonist drug aprepitant by NMR and crystallography.

Authors:  Shuanghong Chen; Mengjie Lu; Dongsheng Liu; Lingyun Yang; Cuiying Yi; Limin Ma; Hui Zhang; Qing Liu; Thomas M Frimurer; Ming-Wei Wang; Thue W Schwartz; Raymond C Stevens; Beili Wu; Kurt Wüthrich; Qiang Zhao
Journal:  Nat Commun       Date:  2019-02-07       Impact factor: 14.919

Review 4.  The Significance of NK1 Receptor Ligands and Their Application in Targeted Radionuclide Tumour Therapy.

Authors:  Agnieszka Majkowska-Pilip; Paweł Krzysztof Halik; Ewa Gniazdowska
Journal:  Pharmaceutics       Date:  2019-09-01       Impact factor: 6.321

5.  Selective G protein signaling driven by substance P-neurokinin receptor dynamics.

Authors:  Julian A Harris; Bryan Faust; Arisbel B Gondin; Marc André Dämgen; Carl-Mikael Suomivuori; Nicholas A Veldhuis; Yifan Cheng; Ron O Dror; David M Thal; Aashish Manglik
Journal:  Nat Chem Biol       Date:  2021-10-28       Impact factor: 15.040

Review 6.  The Structural Basis of Peptide Binding at Class A G Protein-Coupled Receptors.

Authors:  Oanh Vu; Brian Joseph Bender; Lisa Pankewitz; Daniel Huster; Annette G Beck-Sickinger; Jens Meiler
Journal:  Molecules       Date:  2021-12-30       Impact factor: 4.411

7.  In Vivo, In Vitro and In Silico Studies of the Hybrid Compound AA3266, an Opioid Agonist/NK1R Antagonist with Selective Cytotoxicity.

Authors:  Joanna Matalińska; Piotr F J Lipiński; Piotr Kosson; Katarzyna Kosińska; Aleksandra Misicka
Journal:  Int J Mol Sci       Date:  2020-10-19       Impact factor: 5.923

Review 8.  Novel Molecular Targets of Antidepressants.

Authors:  Małgorzata Jarończyk; Jarosław Walory
Journal:  Molecules       Date:  2022-01-14       Impact factor: 4.411

9.  Structures of neurokinin 1 receptor in complex with Gq and Gs proteins reveal substance P binding mode and unique activation features.

Authors:  Cristian Thom; Janosch Ehrenmann; Santiago Vacca; Yann Waltenspühl; Jendrik Schöppe; Ohad Medalia; Andreas Plückthun
Journal:  Sci Adv       Date:  2021-12-08       Impact factor: 14.136

10.  The Neurokinin-1 Receptor Is a Target in Pediatric Rhabdoid Tumors.

Authors:  Julian Kolorz; Salih Demir; Adrian Gottschlich; Iris Beirith; Matthias Ilmer; Daniel Lüthy; Christoph Walz; Mario M Dorostkar; Thomas Magg; Fabian Hauck; Dietrich von Schweinitz; Sebastian Kobold; Roland Kappler; Michael Berger
Journal:  Curr Oncol       Date:  2021-12-26       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.